摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-甲氧基-2-甲基吲哚嗪 | 610766-99-9

中文名称
1-甲氧基-2-甲基吲哚嗪
中文别名
——
英文名称
1-methoxy-2-methylindolizine
英文别名
——
1-甲氧基-2-甲基吲哚嗪化学式
CAS
610766-99-9
化学式
C10H11NO
mdl
——
分子量
161.203
InChiKey
CJRWNGIEWYSHCZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.06±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    13.6
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    1-甲氧基-2-甲基吲哚嗪铁粉potassium carbonate溶剂黄146三乙胺 作用下, 以 乙醇1,2-二氯乙烷N,N-二甲基甲酰胺甲苯 为溶剂, 反应 8.08h, 生成 ethyl 6-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate
    参考文献:
    名称:
    [EN] INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
    [FR] DÉRIVÉS DE L'INDOLIZINE, PROCÉDÉ POUR LEUR PRÉPARATION, ET LEUR UTILISATION THÉRAPEUTIQUE
    摘要:
    该发明涉及与以下式(I)相对应的化合物:N R1 O R3 R4 R2(I),其中- R3和R4与它们附着的苯环的碳原子一起形成一个与下面的式(A)、(B)或(C)之一相对应的6元氮杂环:N N O O Ra Ra' N N O Rb Rb' N O Rc Rc'' Rc'(A)(B)(C),其中波浪线代表R3和R4附着的苯环。制备过程和治疗用途。
    公开号:
    WO2012004731A1
  • 作为产物:
    参考文献:
    名称:
    Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them
    摘要:
    本发明涉及新型1,2,3-取代吲哚嗪衍生物,它们是成纤维细胞生长因子的抑制剂,涉及制备这种衍生物的方法,涉及包含这种衍生物的制药组合物,以及涉及使用这种衍生物的治疗方法。
    公开号:
    US20090023770A1
点击查看最新优质反应信息

文献信息

  • Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same
    申请人:Badorc Alain
    公开号:US20050203126A1
    公开(公告)日:2005-09-15
    Compounds of formula I or salts thereof: in which R 1 represents —OH, (C 1 -C 5 )alkoxy, carboxyl, (C 2 -C 6 )alkoxycarbonyl, —NR 5 R 6 , —NH—SO 2 -Alk, —NH—SO 2 -Ph, —NH—CO-Ph, —N(Alk)-CO-Ph, —NH—CO—NH-Ph, —NH—CO-Alk, —NH—CO 2 -Alk, —O—(CH 2 ) n -cAlk, —O-Alk-COOR 7 , —O-Alk-O—R 8 , —O-Alk-OH, —O-Alk-C(NH 2 ):NOH, —O-Alk-NR 5 R 6 , —O-Alk-CN, —O—(CH 2 ) n -Ph, —O-Alk-CO—NR 5 R 6 , —CO—NH—(CH 2 ) m —COOR 7 , —CO—NH-Alk R 2 represents H, (C 1 -C 5 )alkyl, (C 1 -C 5 )alkyl halide, (C 3 -C 6 )cycloalkyl or phenyl which is optionally substituted, A represents —CO—, —SO— or —SO 2 —, R 3 and R 4 which are identical or different, each represent H, (C 1 -C 5 )alkoxy, amino, carboxyl, (C 2 -C 6 )alkoxycarbonyl, —OH, nitro, hydroxyamino, -Alk-COOR 7 , —NR 5 R 6 , —NH-Alk-COOR 7 , —NH—COO-Alk, —N(R 11 )—SO 2 -Alk-NR 9 R 10 , —N(R 11 )—SO 2 -Alk, —N(R 11 )-Alk-NR 5 R 6 , —N(R 11 )—CO-Alk-NR 9 R 10 , —N(R 11 )—CO-Alk, —N(R 11 )—CO—CF 3 , —NH-Alk-HetN, —O-Alk-NR 9 R 10 , —O-Alk-CO—NR 5 R 6 , —O-Alk-HetN, or R 3 and R 4 form together a 5- to 6-membered unsaturated heterocycle, are inhibitors of basic fibroblast growth factors.
    化学式I或其盐的化合物:其中R1代表—OH,(C1-C5)烷氧基,羧基,(C2-C6)烷氧羰基,—NR5R6,—NH—SO2-Alk,—NH—SO2-Ph,—NH—CO-Ph,—N(Alk)-CO-Ph,—NH—CO—NH-Ph,—NH—CO-Alk,—NH—CO2-Alk,—O—(CH2)n-烷基,—O-Alk-COOR7,—O-Alk-O—R8,—O-Alk-OH,—O-Alk-C(NH2):NOH,—O-Alk-NR5R6,—O-Alk-CN,—O—(CH2)n-Ph,—O-Alk-CO—NR5R6,—CO—NH—(CH2)m—COOR7,—CO—NH-AlkR2代表H,(C1-C5)烷基,(C1-C5)烷基卤化物,(C3-C6)环烷基或苯基,可选择性地取代,A代表—CO—,—SO—或—SO2—,R3和R4相同或不同,各自代表H,(C1-C5)烷氧基,氨基,羧基,(C2-C6)烷氧羰基,—OH,硝基,羟胺基,-Alk-COOR7,—NR5R6,—NH-Alk-COOR7,—NH—COO-Alk,—N(R11)—SO2-Alk-NR9R10,—N(R11)—SO2-Alk,—N(R11)-Alk-NR5R6,—N(R11)—CO-Alk-NR9R10,—N(R11)—CO-Alk,—N(R11)—CO—CF3,—NH-Alk-HetN,—O-Alk-NR9R10,—O-Alk-CO—NR5R6,—O-Alk-HetN,或R3和R4共同形成5-至6-成员不饱和杂环,是基本成纤维细胞生长因子的抑制剂。
  • 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same
    申请人:Sanofi-Aventis
    公开号:US07442708B2
    公开(公告)日:2008-10-28
    Compounds of formula I or salts thereof: in which R1 represents —OH, (C1-C5)alkoxy, carboxyl, (C2-C6)alkoxycarbonyl, —NR5R6, —NH—SO2-Alk, —NH—SO2-Ph, —NH—CO-Ph, —N(Alk)-CO-Ph, —NH—CO—NH-Ph, —NH—CO-Alk, —NH—CO2-Alk, —O—(CH2)n-cAlk, —O-Alk-COOR7, —O-Alk-O—R8, —O-Alk-OH, —O-Alk-C(NH2):NOH, —O-Alk-NR5R6, —O-Alk-CN, —O—(CH2)n-Ph, —O-Alk-CO—NR5R6, —CO—NH—(CH2)m—COOR7, —CO—NH-Alk R2 represents H, (C1-C5)alkyl, (C1-C5)alkyl halide, (C3-C6)cycloalkyl or phenyl which is optionally substituted, A represents —CO—, —SO— or —SO2—, R3 and R4 which are identical or different, each represent H, (C1-C5)alkoxy, amino, carboxyl, (C2-C6)alkoxycarbonyl, —OH, nitro, hydroxyamino, -Alk-COOR7, —NR5R6, —NH-Alk-COOR7, —NH—COO-Alk, —N(R11)—SO2-Alk-NR9R10, —N(R11)—SO2-Alk, —N(R11)-Alk-NR5R6, —N(R11)—CO-Alk-NR9R10, —N(R11)—CO-Alk, —N(R11)—CO—CF3, —NH-Alk-HetN, —O-Alk-NR9R10, —O-Alk-CO—NR5R6, —O-Alk-HetN, or R3 and R4 form together a 5- to 6-membered unsaturated heterocycle, are inhibitors of basic fibroblast growth factors.
    化合物I的公式或其盐: 其中 R1代表-OH,(C1-C5)烷氧基,羧基,(C2-C6)烷氧羰基,-NR5R6,-NH-SO2-Alk,-NH-SO2-Ph,-NH-CO-Ph,-N(Alk)-CO-Ph,-NH-CO-NH-Ph,-NH-CO-Alk,-NH-CO2-Alk,-O-(CH2)n-烷基,-O-Alk-COOR7,-O-Alk-O-R8,-O-Alk-OH,-O-Alk-C(NH2):NOH,-O-Alk-NR5R6,-O-Alk-CN,-O-(CH2)n-Ph,-O-Alk-CO-NR5R6,-CO-NH-(CH2)m-COOR7,-CO-NH-Alk R2代表H,(C1-C5)烷基,(C1-C5)烷基卤代,(C3-C6)环烷基或苯基,可选地取代 A代表-CO-,-SO-或-SO2- R3和R4相同或不同,每个代表H,(C1-C5)烷氧基,氨基,羧基,(C2-C6)烷氧羰基,-OH,硝基,羟基氨基,-Alk-COOR7,-NR5R6,-NH-Alk-COOR7,-NH-COO-Alk,-N(R11)-SO2-Alk-NR9R10,-N(R11)-SO2-Alk,-N(R11)-Alk-NR5R6,-N(R11)-CO-Alk-NR9R10,-N(R11)-CO-Alk,-N(R11)-CO-CF3,-NH-Alk-HetN,-O-Alk-NR9R10,-O-Alk-CO-NR5R6,-O-Alk-HetN,或R3和R4一起形成5-至6-成员的不饱和杂环,是基本成纤维细胞生长因子的抑制剂。
  • 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them
    申请人:Sanofi-Aventis
    公开号:US07803811B2
    公开(公告)日:2010-09-28
    The present invention relates to novel 1,2,3-substituted indolizine derivative which are inhibitors of fibroblast growth factors, to methods or preparing such derivatives, to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising such derivatives.
    本发明涉及一种新型的1,2,3-取代吲哚嗪衍生物,其为成纤维细胞生长因子的抑制剂,以及制备这种衍生物的方法,包括含有这种衍生物的制药组合物,以及包括这种衍生物的治疗方法。
  • Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
    申请人:Alcouffe Chantal
    公开号:US08859544B2
    公开(公告)日:2014-10-14
    The invention relates to compounds corresponding to formula (I): in which R3 and R4 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: in which the wavy lines represent the phenyl nucleus to which R3 and R4 are attached. Preparation process and therapeutic use.
    本发明涉及与公式(I)相对应的化合物:其中R3和R4与它们附着的苯环的碳原子一起形成一个6元氮杂环,该6元氮杂环对应于以下公式(A)、(B)或(C)之一:其中波浪线代表R3和R4附着的苯环。制备方法和治疗用途。
  • INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
    申请人:Alcouffe Chantal
    公开号:US20130116249A1
    公开(公告)日:2013-05-09
    The invention relates to compounds corresponding to formula (I): in which R 3 and R 4 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: in which the wavy lines represent the phenyl nucleus to which R 3 and R 4 are attached. Preparation process and therapeutic use.
    本发明涉及与式(I)相对应的化合物: 其中,R3和R4与它们所连接的苯环的碳原子一起形成一个6元氮杂环,该环对应于下列式之一:(A)、(B)或(C)式: 其中,波浪线代表连接R3和R4的苯环。 该化合物的制备过程和治疗用途。
查看更多

同类化合物

(4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 骆驼蓬酸 顺-六氢-1H-吡咯并[3,2-B]吡啶-4(2H)-羧酸叔丁基酯 螺哌啶-4,3’-3H吡咯并[2,3-b]吡啶-2’(1’H)-酮 螺[哌啶-4,3'-吡咯并[2,3-B]吡啶]-2'(1'H)-酮盐酸盐 莫西沙星杂质69 苹果酸法米替尼 苯乙胺,a,4-二甲基-b-苯基- 苄基-11氢吡咯并[3,4-B]吡啶 罗沙布林 甲基6-甲酰基-1-甲基-1H-吡咯并[3,2-b]吡啶-2-羧酸酯 甲基5-氰基-1H-吡咯并[2,3-b]吡啶-2-羧酸酯 甲基1H-吡咯并[2,3-B]吡啶-5-甲酸酯 甲基-1-甲氧基-4-吡咯并[3,2-c]吡啶 甲基 5-硝基-1H-吡咯并[2,3-B]吡啶-2-羧酸 环戊二烯并[4,5]吡咯并[2,3-B]吡啶,5,6,7,8-四氢 氧代-(1H-吡咯并[2,3-b]吡啶-3-基)-乙酸甲酯 培西达替尼盐酸盐 培西达替尼 吲嗪 吲哚嗪-6-羧酸乙酯 吲哚嗪-3-甲腈 吲哚嗪-2-羧酸甲酯 吲哚嗪-2-羧酸 叔丁基八氢-1H-吡咯并[2,3-c]吡啶-6-羧酸盐 叔丁基5-溴-7-氯-3-碘-1H-吡咯并[2,3-c]吡啶-1-羧酸盐 叔丁基5-溴-7-氯-1H-吡咯并[2,3-c]吡啶-1-羧酸盐 叔丁基3-甲酰基-5-甲基-1H-吡咯并[2,3-b]吡啶-1-羧酸盐 叔丁基3-(3-羟丙基-1-炔基)-5-甲基-1H-吡咯并[2,3-b]吡啶-1-羧酸盐 叔丁基(5-甲基-1H-吡咯并[2,3-b]吡啶-3-基)氨基甲酸酯 叔丁基((5-氟代-1H-吡咯并[2,3-b]吡啶-4-基)甲基氨基甲酸酯 反式-六氢-1H-吡咯并[3,4-C]吡啶-5(6H)-羧酸叔丁酯 化合物 T28221 八氢吡咯并[3.4-b]吡啶-1-羧酸叔丁酯 八氢吡咯并[3,4-b]吡啶 八氢-吡咯[3,4-C]吡啶-2-甲酸叔丁酯 八氢-6-(苯基甲基)-1H-吡咯并[3,4-b]吡啶-1-羧酸 1,1-二甲基乙酯 八氢-1H-吡咯并[3,4-C]吡啶 二苯基(吡咯并[2,3-b]吡啶-1-基)膦 二乙基1H-吡咯并[2,3B]吡啶-2,6-二甲酸基酯 乙基7-氯-3-甲基-1H-吡咯并[3,2-b]吡啶-2-甲酸基酯 乙基7-氮杂吲哚-4-羧酸酯 乙基4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-吡咯并[2,3-b]吡啶-2-羧酸酯 乙基3-氨基-2-吲嗪羧酸酯 乙基1-乙基-1H-吡咯并[3,2-c]吡啶-6-羧酸酯 中氮茚-7-羧酸甲酯 中氮茚-6-羧酸 中氮茚-1-甲酸甲酯 中氮茚-1-甲酸 中氮茚,1-[[4-(3-溴丙氧基)苯基]磺酰]-2-乙基-